CHICAGO: MedAvante, Inc., the leading global scientific clinical data services company today presented new research at the 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy. The new study is the first examination of actual clinical trial outcomes to determine the extent of error reduction with a digital solution such as the Virgil Investigative Study Platform, which uses a tablet device to administer and score clinical outcome assessments (eCOA) and capture source data (eSource), compared with traditional paper-and-pencil methods.
“This is a compelling demonstration of the clinical value of the Virgil eCOA platform,” said Christopher Randolph, PhD, Clinical Professor of Neurology at Loyola University Medical Center and Vice President, Neurocognition at MedAvante.
“The Virgil platform substantially reduced error rates compared to paper-based assessments across four widely used clinical rating scales,” said Randolph. “Error reductions ranged from approximately 50% to over 80% by scale, all of them highly statistically significant.”